Top Stories
The company said its oral PK activator still has potential as a next-generation treatment for sickle-cell disease, where Phase II topline data are due next half.
The deal includes antibody-drug conjugates with unique payloads and multi-specific antibodies with differentiated immune-engaging features.
An FDA panel recommended seasonal COVID-19 vaccines target the XFG variant, while Sanofi's venglustat and Beren's adrabetadex now have November PDUFA dates.
The label expansion comes about a year after the FDA approved AstraZeneca's PD-L1 inhibitor for patients with cisplatin-eligible muscle-invasive bladder cancer.
Last year, CVS had struck a deal to make Novo Nordisk's competing GLP-1 drug Wegovy the preferred obesity treatment on its standard formularies, while excluding Zepbound.
Conference News
SHANGHAI, May 29, 2026 /PRNewswire/ -- Innogen (HKEX: 2591), a biopharmaceutical company dedicated to the discovery, development and commercialization of innovative therapies for metabolic diseases, t...
ZEGFROVY® demonstrated superior anti-tumor efficacy compared to platinum-doublet chemotherapy as a first-line treatment for advanced NSCLC with EGFR exon20insWU-KONG28 is the first global randomized p...
Building on the recent approval of Johnson & Johnson's TECVAYLI® plus DARZALEX FASPRO®, MajesTEC-9 is the second positive Phase 3 study to reinforce the strength of TECVAYLI® as early as second lineTE...
Two virtual posters accepted exploring rejections in oncology marketing applications and real-world pulmonary safety of T-DXd in HER2-positive metastatic breast cancerFrom Insights to Life campaign re...
SAN DIEGO, May 28, 2026 /PRNewswire/ -- Phanes Therapeutics, Inc. (Phanes), a clinical stage biotech company focused on innovative drug discovery and development in oncology, released updated positive...
